Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: Preclinical efficacy and safety in db/db mice

Life Sciences

Volumn 81, Issue 1, 2007, Pages 72-79

  Roy, Subhasis ^a   Khanna, Vivek ^a   Mittra, Shivani ^a   Dhar, Arti ^a   Singh, Shuchita ^a   Mahajan, Dipak C ^a   Priyadarsiny, Priyanka ^a   Davis, Joseph A ^a   Sattigeri, Jitendra ^a   Saini, Kulvinder S ^a   Bansal, Vinay S ^a  

^a RANBAXY RESEARCH LABORATORIES   (India)

Author keywords

dipeptidyl peptidase IV (DPP IV); Haemodilution; LAF 237 (vildagliptin); Oedema and db db mice; Peroxisome proliferator activated receptor gamma (PPAR ); Thiazolidinedione (TZD); Weight gain

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN; INSULIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; SODIUM CHANNEL; VILDAGLIPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EDEMA; ERYTHROCYTE COUNT; FEMALE; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HEMODILUTION; HEMOGLOBIN DETERMINATION; LOW DRUG DOSE; MALE; MONOTHERAPY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; WEIGHT GAIN;

ADAMANTANE; ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; PYRROLIDINES; THIAZOLIDINEDIONES; TRIGLYCERIDES;

MUS;

EID: 34249979025     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2007.04.026     Document Type: Article

References (36)

1. Ahren B. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Expert Opinion on Investigational Drugs 15 4 (2006) 431-442
2. Arakawa K., Ishihara T., Aoto M., Inamasu M., Kitamura K., and Saito A. An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats. Clinical and Experimental Pharmacology and Physiology 31 1-2 (2004) 8-13
3. Barlocco D. LAF-237. Current opinion in Investigational drugs 5 10 (2004) 1094-1100
4. Cavaghan M.A., Ehrmann D.A., and Polonsky K.S. Interaction between insulin resistance and insulin secretion in the development of glucose intolerance. Journal of Clinical Investigation 106 3 (2000) 329-333
5. Chakrabarti R., Vikramadithyan R.K., Misra P., Hiriyan J., Raichur S., Damarla R.K., Gershome C., Suresh J., and Rajagopalan R. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. British Journal of Pharmacology 140 3 (2003) 527-537
6. Chaput E., Saladin R., Silvestre M., and Edgar A.D. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochemical and Biophysical Research Communications 271 2 (2000) 445-450
7. Conarello S.L., Li Z., Ronan J., Roy R.S., Zhu L., Jiang G., Liu F., Woods J., Zycband E., Moller D.E., Thornberry N.A., and Zhang B.B. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proceedings of National Academy of Sciences 100 11 (2003) 6825-6830
8. + transport. Journal of Membrane Biology 184 3 (2001) 313-319
9. Giorgino F., Laviola L., and Leonardini A. Pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategies. Diabetes Research and Clinical Practice 68 1 (2005) S22-S29
10. Guan Y., Hao C., Cha D.R., Rao R., Lu W., Kohan D.E., Magnuson M.A., Redha R., Zhang Y., and Breyer M.D. Thiazolidinone expand body fluid volume through PPAR gamma stimulation of EnaC-mediated renal salt absorption. Nature Medicine 11 8 (2005) 861-866
11. Hansotia T., Baggio L., Delmeire D., Hinke S.A., Yamada Y., Tsukiyama K., Seino Y., Holst J.J., Schuit F., and Drucker D.J. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP IV inhibitors. Diabetes 53 5 (2004) 1326-1335
12. Harrity T., Farrelly D., Tieman A., Chu C., Kunselman L., Gu L., Ponticiello R., Cap M., Qu F., Shao C., Wang W., Zhang H., Fenderson W., Chen S., Devasthali P., Jeon Y., Seethala R., Yang W.P., Ren J., Zhou M., Ryono D., Biller S., Mookhtiar K.A., Wetteran J., Gregg R., Cheng P.T., and Hariharan N. Muraglitazar, a novel dual (alpha/gamma) PPAR activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice. Diabetes 55 1 (2006) 240-248
13. Hollenberg N.K. Considerations for management of fluid dynamic issues associated with thiazolidinediones. American Journal of Medicine 115 l8 (2003) 111S-115S
14. Holst J.J., and Deacon C.F. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 47 11 (1998) 1663-1670
15. Holst J.J., and Orskov C. The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism. Diabetes 53 3 (2004) S197-S204
16. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. Journal of American Medical Association 287 3 (2002) 360-372
17. Kersten S., Desvergne B., and Wahli W. Roles of PPARs in health and disease. Nature 405 6785 (2000) 421-424
18. Lebovitz E.H. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 86 1 (2001) 280-288
19. Lebovitz H.E. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metabolism Research Review 18 Suppl 2 (2002) S23-S29
20. Louche K., Nibbelink M., Prunet B., Bross A., Desbazeille M., Dacquet C., Renard P., Casteilla L., and Penicaud L. Fenofibrate prevents rosiglitazone-induced body weight gain in ob/ob mice. International Journal of Obesity 29 7 (2005) 864-871
21. Mittra S., Sangle G., Tandon R., Sharma S., Roy S., Khanna V., Gupta A., Sattigeri J., Sharma L., Priyadarsiny P., Khattar S.K., Bora R.S., Saini K.S., and Bansal V.S. Increase in weight induced by muraglitazar, a dual PPAR α/γ agonist, in db/db mice: adipogenesis/or oedema. British Journal of Pharmacology 150 4 (2007) 480-487
22. Moller D.E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414 6865 (2001) 821-827
23. Nagakura T., Yasuda N., Yamazaki K., Ikuta H., and Tanaka I. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition. Metabolism 52 1 (2003) 81-86
24. Nauck M.A., Baller B., and Meier J.J. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 53 3 (2004) S190-S196
25. Nesto R.W., Bell D., Bonow R.O., Fonseca V., Grundy S.M., Horton E.S., Le Winter M., Porte D., Semenkovich C.F., Smith S., Young L.H., and Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27 1 (2004) 256-263
26. Nourparvar A., Bulotta A., Di Mario U., and Perfetti R. Novel strategies for the pharmacological management of type 2 diabetes. Trends in Pharmacological Sciences 25 2 (2004) 86-91
27. Pickavance L.C., Tadayyon M., Widdowson P.S., Buckingham R.E., and Wilding J.P.H. Therapeutic index for rosiglitazone in dietary obese rats: separation of effect and haemodilution. British Journal of Pharmacology 128 7 (1999) 1570-1576
28. Reifel-Miller A., Otto K., Hawkins E., Barr R., Bensch W.R., Bull C., Dana S., Klausing K., Martin J.A., Rafaeloff-Phail R., Rafizadeh-Montrose C., Rhodes G., Robey R., Rojo I., Rungta D., Snyder D., Wilbur K., Zhang T., Zink R., Warshawsky A., and Brozinick J.T. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia. Molecular Endocrinology 19 6 (2005) 1593-1605
29. Shaw K.M. Overcoming the hurdles to achieving glycemic control. Metabolism 55 5 Suppl 1 (2006) S6-S9
30. Song J., Knepper M.A., Hu X., Verbalis J.G., and Ecelbarger C.A. Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats. Journal of Pharmacology and Experimental Therapeutics 308 2 (2004) 426-433
31. Spiegelman B.M. PPAR-gamma: adipogenic regulator and thiazolidinediones receptor. Diabetes 47 4 (1998) 507-514
32. Takasaki K., Nakajima T., Ueno K., Nomoto Y., and Higo K. Effects of combination treatment with dipeptidyl peptidase IV inhibitor and sulfonylurea on glucose levels in rats. Journal of Pharmacological Sciences 95 2 (2004) 291-293
33. Villhauer E.B., Brinkman J.A., Naderi G.B., Burkey B.F., Dunning B.E., Prasad K., Mangold B.L., Russell M.E., and Hughes T.E. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. Journal of Medicinal Chemistry 46 13 (2003) 2774-2789
34. Yasuda N., Inoue T., Nagakura T., Yamazaki K., Kira K., Saeki T., and Tanaka I. Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats. Journal of Pharmacology and Experimental Therapeutics 310 2 (2004) 614-619
35. Yki-Jarvinen H. Thiazolidinediones. New England Journal of Medicine 351 11 (2004) 1106-1118
36. Zhang H., Zhang A., Kohan D.E., Nelson R.D., Gonazalez F.G., and Yang T. Collecting duct-specific deletion of peroxisome proliferators-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proceedings of National Academy of Sciences 102 26 (2005) 9406-9411